Efficacy and safety of dapagliflozin combined with Bailing Capsule in treatment of patients with diabetic kidney disease
Objective To investigate the efficacy and safety of dapagliflozin combined with Bailing Capsule in the treatment of patients with diabetic kidney disease (DKD). Methods A total of 1 162 patients with early-stage DKD who were admitted to The Affiliated Hospital of Qingdao University from January 2019...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Precision Medicine
2025-08-01
|
| Series: | 精准医学杂志 |
| Subjects: | |
| Online Access: | https://jpmed.qdu.edu.cn/fileup/2096-529X/PDF/1754471557995-2145427717.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective To investigate the efficacy and safety of dapagliflozin combined with Bailing Capsule in the treatment of patients with diabetic kidney disease (DKD). Methods A total of 1 162 patients with early-stage DKD who were admitted to The Affiliated Hospital of Qingdao University from January 2019 to December 2023 were enrolled, and after propensity score matching was performed to balance intergroup covariates, the patients were divided into control group (dapagliflozin monotherapy) and combination group (dapagliflozin+Bailing Capsule) according to their treatment modality, with 417 patients in each group. The two groups were compared in terms of clinical outcome, blood glucose parameters, renal function parameters, safety indicators (liver function and routine blood test results), and the incidence rate of adverse events after 12 months of treatment. Results After 12 months of treatment, the combination group had a significantly better clinical outcome than the control group (Z=2.919,P<0.05); the combination group had reductions in the levels of fasting plasma glucose, 2 hour postprandial glucose, and HbA1c after treatment, with significantly greater reductions in these indicators compared with the control group (t=41.91-59.57,P<0.05). The combination group had significant reductions in serum creatinine, blood urea nitrogen, 24 hour urinary protein, and urinary albumin excretion rate after treatment, with significantly greater reductions in these indicators compared with the control group (t=12.51-154.9,P<0.05). After 12 months of treatment, liver function parameters and routine blood test results remained within normal ranges in both groups, and there were no significant differences between the two groups in the incidence rates of adverse events such as hypoglycemia and urinary tract infection (P>0.05). Conclusion Dapagliflozin combined with Bailing Capsule can significantly reduce the level of blood glucose and improve renal function parameters in patients with DKD, with a better clinical effect than dapagliflozin monotherapy and with a favorable safety profile. |
|---|---|
| ISSN: | 2096-529X |